Business Context and Reporting Period
Company: Evogene Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Filing Date: March 5, 2026
Reporting Period: Fourth Quarter and Full Fiscal Year ended December 31, 2025
This filing serves as a cover document incorporating by reference a press release (Exhibit 99.1) and a conference call slide presentation (Exhibit 99.2) detailing the company's financial results for the specified period.
Key Financial Metrics
The provided text is a cover filing and does not contain specific numerical data. The following metrics are referenced as being available in the attached exhibits but are not listed in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any specific financial metric.
Material Changes
The filing text does not disclose specific material changes, year-over-year comparisons, or variance analysis. Such details are contained within the incorporated press release and slide presentation.
Guidance, Outlook, and Management Commentary
Management Action: Evogene held a conference call on March 5, 2026, to discuss the quarterly results and business outlook.
Documentation: A slide presentation providing additional information regarding the business and financial results was made available to investors (Exhibit 99.2).
Forward-Looking Statements: The text does not contain specific guidance numbers or risk factors; these are presumed to be in the referenced exhibits.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual revenue, net income, and cash flow figures for Q4 and FY 2025.
- Examine Exhibit 99.2 (Slide Presentation) for management's strategic outlook and operational highlights.
- Verify the incorporation of GAAP financial statements into active registration statements (Form F-3 and Form S-8) as noted in the filing.
- Confirm the specific details of the conference call discussion regarding future guidance, which are not present in this cover letter.